Thursday , December 14 2017
Home / Therapies / Bromocriptine-QR (Cycloset) / Impact of Bromocriptine-QR Therapy on Cardiovascular Outcomes in Type 2 Diabetes Mellitus Subjects on Metformin

Impact of Bromocriptine-QR Therapy on Cardiovascular Outcomes in Type 2 Diabetes Mellitus Subjects on Metformin

Given the potential for CVD risk reduction associated with metformin and Bromocriptine-QR therapy (B-QR)  individually, the present study explored the effect of add-on B-QR vs placebo to metformin on CVD outcomes in T2DM subjects.


Click here to download this presentation (Adobe PDF): Impact of Bromocriptine-QR Therapy